Categories AlphaGraphs, Earnings, Health Care

Earnings: Teva Pharma shrinks Q4 losses, but revenue falls

Teva Pharma (TEVA) posted its fourth-quarter 2018 before the opening bell on Feb. 13. The generic drugmaker saw revenue slip 16% to $4.56 billion in the quarter, while net attributable loss shrunk to $2.94 billion or $2.85 per diluted share vs. $11.6 billion or $11.41-a-share in losses a year ago. Non-GAAP profit slipped to $543 million or $0.53 per diluted share, down from last year’s $949 million or $0.93 per share.

The Street expected Teva to post a loss of 53 cents a share on estimated revenue of $4.54 billion. Earnings were more in line with the consensus, but revenue surpassed it by a bit.

Teva Pharmaceuticals fourth quarter earnings infographic

Net non-GAAP adjustments for Teva in the fourth quarter were $3.48billion. Non-GAAP net income and non-GAAP EPS for the fourth quarter were adjusted to exclude a goodwill impairment of $2,73 billion related to International Markets, a $990-million impairment related to the acquisition of Actavis Generics, and other effects and expenses.

 

LOOKING TO 2019

For 2019, Teva sees revenues of $17.0-17.4 billion generating non-GAAP operating income of $3.8-4.2 billion and non-GAAP EPS of $2.20-2.50.

For the coming year, Teva expects continued generic erosion in global COPAXONE sales, touting it to be at about $1.5 billion.

However, the drugmaker expects new launches to offset slight volume decline toNorth America Generics. For International generics, Teva expects an adverse impact in Japan due to NHI price revision and LLP erosion.

 

 

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

PepsiCo likely to report weak Q2 results as North America demand slumps

After entering fiscal 2025 on a low note, PepsiCo, Inc. (NASDAQ: PEP) is gearing up to publish its second-quarter results. The company is facing sales pressure amid geopolitical tensions and

Bank earnings preview: These banking leaders will report Q2 2025 results next week, what to expect

The earnings season is set to kick off next week with quarterly reports from a number of leading banks. JPMorgan Chase & Co. (NYSE: JPM), Citigroup (NYSE: C) and Wells

Johnson & Johnson to report Q2 earnings on July 16. Here’s what to expect

Johnson & Johnson's (NYSE: JNJ) business strategy for fiscal 2025 is focused on reducing the impact of patent expirations on its revenue. Anticipating sales to benefit from growth initiatives, including

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top